ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Management of skin metastases of ovarian cancer: a novel therapeutic approach.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOvarian cancer, one of the most lethal gynecological cancers, metastasizes into skin in 0.9%-5.8% of cases. Cutaneous metastases severely affect the quality of life of ovarian cancer patients. Although cutaneous metastases are rare, a therapeutic option for affected patients is needed. Herein, we present a combination therapy comprising radiation and mild hyperthermia with parallel chemotherapy as a treatment modality. CASE: A woman with extensive skin metastases of a high-grade, serous ovarian carcinoma on the thigh was treated with a combination of mild hyperthermia (39-43 °C) immediately followed by low-dose hypofractionated radiotherapy and parallel systemic treatment with carboplatin/gemcitabine. Mild hyperthermia, a strong radiosensitizer, was induced through water-filtered infrared A radiation (wIRA).
resultsThe patient responded well and remained tumor free in the treatment area for more than 1 year.
conclusionRadiotherapy combined with mild hyperthermia in addition to systemic treatment allows for tumor control in the treated area, even with a reduced total radiation dose. To the best of our knowledge, this is the first report of a long-term tumor-free situation in the treatment area of skin metastases of ovarian cancer. This novel treatment might also be beneficial for skin metastases from other malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.